Thinking and prospect of the application of flow cytometry in laboratory testing of chimeric antigen receptor T cell immunotherapy
10.3760/cma.j.cn114452-20220630-00380
- VernacularTitle:流式细胞术在嵌合抗原受体-T细胞免疫治疗相关实验室检测中应用的思考与展望
- Author:
Hui WANG
1
;
Guijian LIU
Author Information
1. 河北燕达陆道培医院检验科，廊坊065201
- Keywords:
Flow cytometry;
Receptor;
Chimeric antigen;
T cells;
Immunotherapy
- From:
Chinese Journal of Laboratory Medicine
2022;45(8):767-770
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor (CAR)-T cell immunotherapy is one of the most remarkable achievements in the field of cancer therapy for the past few years. Flow cytometry (FCM) plays an important role in the design and construction of CAR-T cells, patient enrollment, performance test of CAR-T products, evaluation of post-treatment efficacy and immune function, exploration of relapse mechanism, and selection of subsequent treatment. In order to further promote and standardize the application of FCM in laboratory testing related to CAR-T cell immunotherapy, the special issue on "Application and Research Progress of flow cytometry in CAR-T cell immunotherapy" were organized by The Chinese Journal of Laboratory Medicine. A number of articles related to this topic were published, which covered expert consensus, continuing education, expert review, detection of minimal residual disease, immune function, and cytokine detection. We intend to promote the standardization of FCM in CAR-T cell immunotherapy and provide greater assistance for clinical application.
